Mallinckrodt Stock Price, News & Analysis (NYSE:MNK)

$16.17 -0.54 (-3.23 %)
(As of 02/22/2018 07:54 AM ET)
Previous Close$16.71
Today's Range$16.15 - $16.91
52-Week Range$15.27 - $55.32
Volume1.59 million shs
Average Volume2.85 million shs
Market Capitalization$1.59 billion
P/E Ratio4.37
Dividend YieldN/A
Beta1.04

About Mallinckrodt (NYSE:MNK)

Mallinckrodt logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio1.08%
Current Ratio1.38%
Quick Ratio1.05%

Price-To-Earnings

Trailing P/E Ratio4.37028208184346
Forward P/E Ratio2.25
P/E Growth0.31

Sales & Book Value

Annual Sales$829.90 million
Price / Sales1.85
Cash Flow$0.24 per share
Price / Cash66.32
Book Value$47.57 per share
Price / Book0.34

Profitability

Trailing EPS$3.70
Net Income$-153,200,000.00
Net Margins11.43%
Return on Equity14.79%
Return on Assets5.07%

Miscellaneous

Employees4,500
Outstanding Shares95,000,000

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt declared that its board has authorized a stock buyback plan on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 18.5% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) released its earnings results on Tuesday, November, 7th. The company reported $1.97 earnings per share for the quarter, topping analysts' consensus estimates of $1.80 by $0.17. The company earned $793.90 million during the quarter, compared to analyst estimates of $808.93 million. Mallinckrodt had a return on equity of 14.79% and a net margin of 11.43%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.04 EPS. View Mallinckrodt's Earnings History.

When will Mallinckrodt make its next earnings announcement?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Mallinckrodt.

Where is Mallinckrodt's stock going? Where will Mallinckrodt's stock price be in 2018?

17 brokerages have issued 1 year price targets for Mallinckrodt's stock. Their forecasts range from $20.00 to $98.00. On average, they anticipate Mallinckrodt's stock price to reach $43.74 in the next year. View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax.  As  a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "Mallinckrodt announced today that it is selling certain hemostasis products to Baxter (BAX, Not Covered), including Recothrom and PreveLeak, for ~ $185MM, with $153MM upfront and the rest in potential milestones. The company will also discontinue marketing of Raplixa and evaluate strategic options for the product." (1/8/2018)
  • 3. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)

Who are some of Mallinckrodt's key competitors?

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:

  • Melvin D. Booth Ph.D. CPA, Independent Chairman of the Board (Age 71)
  • Mark C. Trudeau, President, Chief Executive Officer, Director (Age 55)
  • Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President (Age 46)
  • Ian J. Watkins, Chief Human Resource Officer (Age 54)
  • Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies (Age 56)
  • Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer (Age 51)
  • Steven Romano, Executive Vice President and Chief Scientific Officer (Age 57)
  • Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics (Age 47)
  • Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases (Age 53)
  • Raymond J. Furey, Chief Compliance Officer (Age 48)

Who owns Mallinckrodt stock?

Mallinckrodt's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.99%), Alliancebernstein L.P. (2.77%), LSV Asset Management (2.76%), Two Sigma Investments LP (1.44%), Arrowstreet Capital Limited Partnership (1.43%) and Brandywine Global Investment Management LLC (1.25%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.

Who sold Mallinckrodt stock? Who is selling Mallinckrodt stock?

Mallinckrodt's stock was sold by a variety of institutional investors in the last quarter, including HealthCor Management L.P., BlackRock Inc., UBS Asset Management Americas Inc., Deutsche Bank AG, Alliancebernstein L.P., Teacher Retirement System of Texas, American Financial Group Inc. and Swiss National Bank. View Insider Buying and Selling for Mallinckrodt.

Who bought Mallinckrodt stock? Who is buying Mallinckrodt stock?

Mallinckrodt's stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Arrowstreet Capital Limited Partnership, Schroder Investment Management Group, Two Sigma Advisers LP, LSV Asset Management, Spark Investment Management LLC, Renaissance Technologies LLC and Royce & Associates LP. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.

How do I buy Mallinckrodt stock?

Shares of Mallinckrodt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of Mallinckrodt stock can currently be purchased for approximately $16.17.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $1.59 billion and generates $829.90 million in revenue each year. The company earns $-153,200,000.00 in net income (profit) each year or $3.70 on an earnings per share basis. Mallinckrodt employs 4,500 workers across the globe.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (MNK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  603 (Vote Outperform)
Underperform Votes:  350 (Vote Underperform)
Total Votes:  953
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mallinckrodt (NYSE:MNK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.352.392.442.87
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.74$45.81$49.31$71.37
Price Target Upside: 140.97% upside104.58% upside136.14% upside86.58% upside

Mallinckrodt (NYSE:MNK) Consensus Price Target History

Price Target History for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018BarclaysDowngradeEqual Weight -> Underweight$23.00 -> $20.00MediumView Rating Details
1/9/2018MizuhoReiterated RatingNeutral -> Neutral$22.00 -> $21.00N/AView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetBuy$42.00MediumView Rating Details
1/7/2018Canaccord GenuitySet Price TargetHold$24.00MediumView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$26.00MediumView Rating Details
1/1/2018Wells Fargo & CoReiterated RatingHoldHighView Rating Details
1/1/2018Goldman Sachs GroupReiterated RatingHoldHighView Rating Details
11/22/2017OppenheimerReiterated RatingOutperform -> Market PerformN/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetBuy$70.00 -> $50.00N/AView Rating Details
11/8/2017Morgan StanleyLower Price TargetEqual Weight$40.00 -> $27.00N/AView Rating Details
11/8/2017BMO Capital MarketsLower Price TargetOutperform$38.00N/AView Rating Details
11/8/2017Jefferies GroupInitiated CoverageMarket Perform -> Buy$60.00 -> $30.00N/AView Rating Details
11/7/2017CitigroupDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
11/7/2017Deutsche BankDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$67.00N/AView Rating Details
8/9/2017Raymond James FinancialLower Price TargetOutperform$65.00 -> $58.00LowView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
1/25/2017JPMorgan Chase & Co.Set Price TargetHold$78.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart

Earnings by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$1.69N/AView Earnings Details
11/7/2017Q3 2017$1.80$1.97$808.93 million$793.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Mallinckrodt (NYSE:MNK) Earnings Estimates

2018 EPS Consensus Estimate: $6.89
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.43$1.55$1.48
Q2 20183$1.51$1.79$1.65
Q3 20183$1.58$2.07$1.88
Q4 20183$1.65$1.99$1.87
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Mallinckrodt (NYSE:MNK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.77%
Institutional Ownership Percentage: 97.38%
Insider Trades by Quarter for Mallinckrodt (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2017Dr Kneeland YoungbloodDirectorBuy4,560$21.94$100,046.4019,789View SEC Filing  
11/13/2017Joann A ReedDirectorBuy1,000$21.50$21,500.0015,554View SEC Filing  
11/13/2017Steven J. RomanoVPBuy2,000$21.96$43,920.00View SEC Filing  
11/10/2017Mark TrudeauCEOBuy5,000$22.28$111,400.00View SEC Filing  
11/9/2017David R CarlucciDirectorBuy10,000$21.83$218,300.0026,020View SEC Filing  
11/9/2017Michael-Bryant HicksGeneral CounselBuy7,900$20.80$164,320.00View SEC Filing  
8/30/2017Meredith B. FischerInsiderBuy1,280$39.63$50,726.40View SEC Filing  
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.0031,455View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.5030,955View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.4715,623View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.0056,036View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00192,546View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.009,291View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.0020,556View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.0017,643View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.0017,940View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.0017,340View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.0011,266View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.002,549View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.007,728View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50167,526View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.009,986View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.0014,280View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.001,453View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.449,015View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00166,176View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.007,361View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00165,176View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mallinckrodt (NYSE MNK) News Headlines

Source:
DateHeadline
Zacks: Brokerages Expect Mallinckrodt PLC (MNK) Will Post Quarterly Sales of $776.52 MillionZacks: Brokerages Expect Mallinckrodt PLC (MNK) Will Post Quarterly Sales of $776.52 Million
www.americanbankingnews.com - February 22 at 5:48 AM
Mallinckrodt Earns Somerset County Planning Board Land Development HonorMallinckrodt Earns Somerset County Planning Board Land Development Honor
finance.yahoo.com - February 21 at 8:41 AM
Mallinckrodt (MNK) to Release Quarterly Earnings on TuesdayMallinckrodt (MNK) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:46 AM
We now know how much Sucampo founders made from the companys saleWe now know how much Sucampo founders made from the company's sale
www.bizjournals.com - February 16 at 5:06 PM
Mallinckrodt To Present At Barclays Global Healthcare ConferenceMallinckrodt To Present At Barclays Global Healthcare Conference
finance.yahoo.com - February 15 at 5:07 PM
Sucampo Pharmaceuticals closes on its $1.2B sale to a UK company - Washington Business JournalSucampo Pharmaceuticals closes on its $1.2B sale to a UK company - Washington Business Journal
www.bizjournals.com - February 15 at 8:06 AM
Mallinckrodt (MNK) Announces Enrollment of First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue - StreetInsider.comMallinckrodt (MNK) Announces Enrollment of First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue - StreetInsider.com
www.streetinsider.com - February 15 at 8:06 AM
Mallinckrodt (MNK) Completes Acquisition Of Sucampo ... - StreetInsider.comMallinckrodt (MNK) Completes Acquisition Of Sucampo ... - StreetInsider.com
www.streetinsider.com - February 15 at 8:06 AM
At $15.96, Is Mallinckrodt Public Limited Company (NYSE:MNK) A Buy?At $15.96, Is Mallinckrodt Public Limited Company (NYSE:MNK) A Buy?
finance.yahoo.com - February 14 at 5:17 PM
Mallinckrodt (MNK) Announces Enrollment of First Patient in Phase 1 Study of ExpressGraft C9T1 Skin TissueMallinckrodt (MNK) Announces Enrollment of First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue
www.streetinsider.com - February 14 at 9:41 AM
Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin TissueMallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue
finance.yahoo.com - February 14 at 9:41 AM
Mallinckrodt PLC (MNK) Given Average Rating of "Hold" by BrokeragesMallinckrodt PLC (MNK) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 14 at 5:54 AM
Mallinckrodt (MNK) Completes Acquisition Of Sucampo Pharmaceuticals (SCMP)Mallinckrodt (MNK) Completes Acquisition Of Sucampo Pharmaceuticals (SCMP)
www.streetinsider.com - February 13 at 3:56 PM
Sucampo Pharmaceuticals closes on its $1.2B sale to a U.K. companySucampo Pharmaceuticals closes on its $1.2B sale to a U.K. company
finance.yahoo.com - February 13 at 3:56 PM
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
finance.yahoo.com - February 13 at 9:48 AM
[$$] New Tax Law Haunts Companies That Did ‘Inversion’ Deals[$$] New Tax Law Haunts Companies That Did ‘Inversion’ Deals
finance.yahoo.com - February 12 at 9:40 AM
Mallinckrodt: Is The Generics Sale In Trouble?Mallinckrodt: Is The Generics Sale In Trouble?
seekingalpha.com - February 10 at 9:35 AM
Shareholders sue Sucampo, claim proposed sale undervalues the companyShareholders sue Sucampo, claim proposed sale undervalues the company
www.bizjournals.com - February 5 at 3:54 PM
$776.52 Million in Sales Expected for Mallinckrodt PLC (MNK) This Quarter$776.52 Million in Sales Expected for Mallinckrodt PLC (MNK) This Quarter
www.americanbankingnews.com - February 5 at 4:52 AM
ValuEngine Lowers Mallinckrodt (MNK) to HoldValuEngine Lowers Mallinckrodt (MNK) to Hold
www.americanbankingnews.com - February 4 at 10:18 PM
Barclays Lowers Mallinckrodt (MNK) to UnderweightBarclays Lowers Mallinckrodt (MNK) to Underweight
www.americanbankingnews.com - February 3 at 6:00 PM
Barclays: Mallinckrodts Sucampo Deal Overshadowed By Competitive Threats - BenzingaBarclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats - Benzinga
www.benzinga.com - February 3 at 9:33 AM
Mark Casey Joins Mallinckrodt as General Counsel - PR Newswire (press release)Mark Casey Joins Mallinckrodt as General Counsel - PR Newswire (press release)
www.prnewswire.com - February 3 at 9:33 AM
Barclays Downgrades Mallinckrodt plc (MNK) to Underweight - StreetInsider.comBarclays Downgrades Mallinckrodt plc (MNK) to Underweight - StreetInsider.com
www.streetinsider.com - February 2 at 9:43 AM
Mallinckrodt: Substantial Upside - Seeking AlphaMallinckrodt: Substantial Upside - Seeking Alpha
seekingalpha.com - February 2 at 9:43 AM
Mark Casey Joins Mallinckrodt as General CounselMark Casey Joins Mallinckrodt as General Counsel
finance.yahoo.com - February 1 at 9:47 AM
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary SarcoidosisFirst Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
finance.yahoo.com - January 31 at 10:07 AM
Mallinckrodt International Finance SA -- Moodys confirms Mallinckrodt Ba3 CFR; outlook changed to negativeMallinckrodt International Finance SA -- Moody's confirms Mallinckrodt Ba3 CFR; outlook changed to negative
finance.yahoo.com - January 29 at 3:55 PM
Leerink Swann Comments on Mallinckrodt PLCs FY2017 Earnings (MNK)Leerink Swann Comments on Mallinckrodt PLC's FY2017 Earnings (MNK)
www.americanbankingnews.com - January 29 at 1:08 AM
Mallinckrodt PLC (MNK) Forecasted to Post FY2017 Earnings of $7.07 Per ShareMallinckrodt PLC (MNK) Forecasted to Post FY2017 Earnings of $7.07 Per Share
www.americanbankingnews.com - January 24 at 6:54 AM
Q3 2018 Earnings Forecast for Mallinckrodt PLC (MNK) Issued By OppenheimerQ3 2018 Earnings Forecast for Mallinckrodt PLC (MNK) Issued By Oppenheimer
www.americanbankingnews.com - January 23 at 2:40 PM
Mallinckrodt PLC (MNK) Given Consensus Rating of "Hold" by AnalystsMallinckrodt PLC (MNK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 20 at 5:48 AM
Zacks: Analysts Expect Mallinckrodt PLC (MNK) Will Announce Quarterly Sales of $777.89 MillionZacks: Analysts Expect Mallinckrodt PLC (MNK) Will Announce Quarterly Sales of $777.89 Million
www.americanbankingnews.com - January 19 at 9:10 AM
Zacks: Brokerages Anticipate Mallinckrodt PLC (MNK) to Post $1.72 Earnings Per ShareZacks: Brokerages Anticipate Mallinckrodt PLC (MNK) to Post $1.72 Earnings Per Share
www.americanbankingnews.com - January 17 at 1:18 PM
Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018? - NasdaqEndo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018? - Nasdaq
www.nasdaq.com - January 16 at 5:02 PM
Active-Investors: Blog Exposure - Baxter International Acquires RECOTHROM and PREVELEAK from MallinckrodtActive-Investors: Blog Exposure - Baxter International Acquires RECOTHROM and PREVELEAK from Mallinckrodt
www.finanznachrichten.de - January 10 at 9:54 AM
Blog Exposure - Baxter International Acquires RECOTHROM and PREVELEAK from MallinckrodtBlog Exposure - Baxter International Acquires RECOTHROM and PREVELEAK from Mallinckrodt
finance.yahoo.com - January 10 at 9:54 AM
Mallinckrodt Will Sell RECOTHROM® And PREVELEAK® To BaxterMallinckrodt Will Sell RECOTHROM® And PREVELEAK® To Baxter
finance.yahoo.com - January 8 at 10:03 AM
Mother Alleges Biotech Firm Stole Data From Her Sick ChildrenMother Alleges Biotech Firm Stole Data From Her Sick Children
finance.yahoo.com - January 8 at 10:03 AM
Mallinckrodt PLC (MNK) Forecasted to Earn FY2017 Earnings of $7.20 Per ShareMallinckrodt PLC (MNK) Forecasted to Earn FY2017 Earnings of $7.20 Per Share
www.americanbankingnews.com - January 5 at 8:14 AM
Mallinckrodt Completes Stannsoporfin New Drug Application FilingMallinckrodt Completes Stannsoporfin New Drug Application Filing
finance.yahoo.com - January 4 at 5:04 PM
Mallinckrodt PLC Forecasted to Post Q1 2018 Earnings of $1.39 Per Share (MNK)Mallinckrodt PLC Forecasted to Post Q1 2018 Earnings of $1.39 Per Share (MNK)
www.americanbankingnews.com - January 4 at 11:10 AM
Mallinckrodt plc (MNK) PT Lowered to $37 at Piper Jaffray; Reiterates OverweightMallinckrodt plc (MNK) PT Lowered to $37 at Piper Jaffray; Reiterates Overweight
www.streetinsider.com - January 4 at 9:45 AM
Can Sucampo Acquisition Turn Mallinckrodt Stock Around?Can Sucampo Acquisition Turn Mallinckrodt Stock Around?
finance.yahoo.com - January 3 at 9:04 AM
Moodys Downgrade Could Punish Mallinckrodt - Mallinckrodt PLC ... - Seeking AlphaMoody's Downgrade Could Punish Mallinckrodt - Mallinckrodt PLC ... - Seeking Alpha
seekingalpha.com - January 2 at 11:09 PM
Mallinckrodt (MNK) Coverage Initiated by Analysts at Leerink SwannMallinckrodt (MNK) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - January 2 at 5:18 PM
Mallinckrodt (MNK) Cut to Hold at ValuEngineMallinckrodt (MNK) Cut to Hold at ValuEngine
www.americanbankingnews.com - January 1 at 4:34 PM
Mallinckrodt (MNK) Downgraded by UBS GroupMallinckrodt (MNK) Downgraded by UBS Group
www.americanbankingnews.com - December 31 at 4:22 PM
Mallinckrodt PLC (MNK) to Post FY2018 Earnings of $5.78 Per Share, Cantor Fitzgerald ForecastsMallinckrodt PLC (MNK) to Post FY2018 Earnings of $5.78 Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - December 30 at 7:58 PM
Mallinckrodts (MNK) "Hold" Rating Reiterated at Goldman Sachs GroupMallinckrodt's (MNK) "Hold" Rating Reiterated at Goldman Sachs Group
www.americanbankingnews.com - December 29 at 11:34 PM

SEC Filings

Mallinckrodt (NYSE:MNK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mallinckrodt (NYSE MNK) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.